Sirolimus inhibits oxidative burst activity in transplant recipients

Transplantation

Volumn 76, Issue 12, 2003, Pages 1766-1768

  Gee, Ian ^a   Trull, Andrew K ^a   Charman, Susan C ^b   Alexander, Graeme J M ^a,c  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN; CALCINEURIN INHIBITOR; CYCLOSPORIN; PHORBOL 13 ACETATE 12 MYRISTATE; PROPOFOL; RAPAMYCIN; TACROLIMUS;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; GRAFT REJECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; INFECTION SENSITIVITY; KIDNEY TRANSPLANTATION; LEUKOCYTE ACTIVATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY BURST;

ADULT; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; REFERENCE VALUES; RESPIRATORY BURST; SIROLIMUS; TETRADECANOYLPHORBOL ACETATE;

EID: 0347363455     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000093995.08240.49     Document Type: Article

References (10)

1. Groth CG, Backman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European renal transplant study group. Transplantation 1999; 67: 1036.
2. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
3. Hadley S, Samore MH, Lewis WD, et al. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851.
4. Morel F, Doussiere J, Vignais PV. The superoxide-generating oxidase of phagocytic cells. Physiological, molecular and pathological aspects. Eur J Biochem 1991; 201: 523.
5. Heine J, Leuwer M, Scheinichen D, et al. Flow cytometry evaluation of the in vitro influence of four i.v. anaesthetics on respiratory burst of neutrophils. Br J Anaesth 1996; 77: 387.
6. Wang JE, Solberg R, Okkenhaug C, et al. Cytokine modulation in experimental endotoxemia: characterization of an ex vivo whole blood model. Eur Surg Res 2000; 32: 65.
7. Yatscoff R, LeGatt D, Keenan R, et al. Blood distribution of rapamycin. Transplantation 1993; 56: 1202.
8. Mazoit JX, Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br J Clin Pharmacol 1999; 47: 35.
9. MacDonald A, Scarola J, Burke JT, et al. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl B): B101.
10. Rokaw MD, West M, Johnson JP. Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells. J Biol Chem 1996; 271: 32468.